Alithia Life Sciences’ Post

EFPIA's article discusses the potential of Precision Oncology (PO) in Europe beyond 2025. 🌍 1️⃣ PO aims to tailor cancer treatments to individual biological characteristics, improving patient outcomes. 2️⃣ Significant disparities in PO infrastructure and access across Europe highlight the need for aligned policies and investments. 📊 Could the uneven distribution of PO resources in Europe hinder the fight against cancer, and what can be done to ensure equitable access? #PrecisionOncology #HealthEquality #FutureOfCancerTreatment For more details, you can read the full article below. https://lnkd.in/d7aDNFFn EFPIA - European Federation of Pharmaceutical Industries and Associations

📣 NEWS 1️⃣ MARCH: We are excited to launch our entirely revised website. ➡ It provides clarity on our main pillars of product offerings, the GENESIS platform of glycopeptide products, and their main Mode-Of-Action, as well as the announcement that we are going full speed towards IND submission by end of 2024. 🔜 WHAT does that mean? We will be going into first-in-human clinical phase 1 studies in the lead indication - MSS colorectal cancer - which represents a high unmet need for patients because traditional I/O therapies have been unsuccessful so far. ↪ WHY that is important? Because Gnubiotics' proprietary platform of glycopeptide biologics have completed their preclinical evidence of 🌟 breaking through I/O resistance, 🌟 being orally available, 🌟 in an entire new class of anti-cancer agents. 💡 Check it out here 🌐 https://gnubiotics.com/ 〰 Follow us on this page to stay up-to-date with news on data, people, and clinical trial IND progress.

Join Consilium for our first post-summer event on Thursday, 5th September! ❓ Do we need Phase 3 trials in oncology? 📅 Thursday 5th September, 5pm London Time 🎫 Sign up here: https://lnkd.in/djYW5eQu Waste in cancer research has been disappointing to many whilst allowing significant capitalisation for pharmaceutical industry. Many improvements have been made and many more are yet to come. How should cancer research evolve? How can we decrease the waste and ensure better selection of pre-clinical models moving to clinic? Will we need phase 3 trials and what role RWE evidence will play? Will synthetic comparators give answers clinical practice needs? How can we overcome current incentives in the oncology market and stop over-production of expensive me-toos? In conversation with Marty Tenenbaum, Julian Adams, Ian Tannock and Jonathan Kimmelman.

🎉 Congratulations Nicki Meagher, PhD on being awarded a #SydneyCancerPartners #SeedGrant Project title: “Utilisation of publicly funded PARP inhibitors in ovarian cancer in New South Wales: a population-based study.” This seed grant will enable a population-based analysis of the utilisation of an important targeted therapy now available to many patients with ovarian cancer – olaparib. Through a collaboration with the Centre of Research Excellence in Medicines Intelligence led from UNSW Sydney, Nicki will analyse the patterns of use of olaparib using Pharmaceutical Benefits Scheme (PBS) linked data. Following PBS, listing there is a need to understand the uptake and outcomes of cancer medicines in routine care, to help inform policy and clinical decision making. Read more: https://lnkd.in/eWMdayay

Targeted therapies have been a game-changer in the fight against cancer. These innovative treatments are designed to specifically target molecules or pathways involved in the growth and survival of cancer cells. The benefits of targeted therapies are significant and multifaceted, ranging from clinical benefits to market differentiation. They also play a crucial role in shaping the future of personalized medicine, making them a key area of focus for the pharmaceutical industry. #targetedtherapy #cancerresearch #personalizedmedicine #biomarkerdiscovery #biomarkers #clinicaldevelopment #precisiononcology #precisionhealth #futurehealthcare

On Tuesday 25 June we will host a special webinar tailored for oncology applications. Reserve your spot today: https://lnkd.in/eu__ZVSK Formulators and developers face a significant challenge. During this webinar, we will evaluate stability data of several small molecule drugs for cancer. Degradation and instability in chemotherapeutics can lead to: - Extended development timelines - Regulatory challenges - Compromised product efficacy. This ultimately delays lifesaving treatments for those who need it most - the patients. We will show you how we can optimise oncological drug delivery resulting in long-term formulation stability, extended drug shelf life, and ultimately improved drug performance and efficacy.

#Immuno_Oncology_Therapy Market Growing Popularity and Emerging Trends 2023 to 2032 >> https://lnkd.in/gsP7pYQM #Immuno oncology #therapy has become one of the most #popular methods used to #treat different types of #cancer. This therapy #artificially stimulates an individual's #immune #system to enhance its #ability to #fight against cancerous #cells. Amgen, AstraZeneca, Bristol Myers Squibb, Roche, GSK, Janssen Biotech, Inc., Merck Group, Novartis, Pfizer, Sanofi #immunooncology #therapy #treatcancer #artificially #immunesystem #medicalscience #biotechnology #healthcareindustry

When faced with scaling up the development and manufacture of their innovative cancer drug Deflexifol™, our customers at FivepHusion teamed up with our team of Pfizer experts. By leveraging our deep expertise in handling critical drug constituents and scaling cytotoxic drugs, FivepHusion were able to successfully de-risk their journey to market. But how did we do it? Read the full case study below to find out. 👇 https://lnkd.in/enej3-Af #CDMO #DrugDevelopment #DrugManufacturing

[Deals] 1. Bristol Myers Squibb acquires RayzeBio, inc. for $4.10 billion, gains rights to RYZ101 (225Ac-DOTATATE) for gastroenteropancreatic neuroendocrine tumors and expands radiopharmaceutical portfolio ⏩ https://lnkd.in/gwNcXBtZ 2. AstraZeneca signs $1.2bn acquisition deal with Gracell Biotechnologies for innovative CAR-T therapy GC012F targeting multiple myeloma and autoimmune diseases ⏩ https://lnkd.in/gmyhpHcV 3. LianBio signs license agreement with Janssen for NBTXR3, head and neck cancer radioenhancer, with $25 million upfront payment and up to $5 million in milestone payments ⏩ https://lnkd.in/gY_z3iq4

Looking forward to sharing some of our latest advances with solid tumor predictive response signatures in tissue and now #liquidbiopsy #precisionmedicine #oncology #diagnostics